A Double Blind, Randomized, Placebo-controlled, Parallel Group Study, for the Assessment of Efficacy, Safety and Tolerability of Brivaracetam at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post-herpetic Neuralgia (PHN)
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2017
At a glance
- Drugs Brivaracetam (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 16 Jul 2007 Status changed from in progress to completed.
- 18 Dec 2005 New trial record.